Advertisement

Topics

Search Results for "Xarelto Vs Pradaxa"

04:55 EST 28th February 2017 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Some Increased Bleeding Risk Seen With Blood Thinner Xarelto Vs. Pradaxa

MONDAY, Oct. 3, 2016 -- The blood thinner Xarelto may pose a slightly greater risk of serious bleeding than Pradaxa in patients with the abnormal heartbeat known as atrial fibrillation, new research s...

BRIEF-Bayer comments on the article in "Handelsblatt" on Xarelto

* Believes statements published in 'Handelsblatt' on Nov. 9. about Xarelto are misleading

Boehringer Ingelheim Presents Real-world Analysis of Pradaxa Users

NewsPharmaceutical company Boehringer Ingelheim Pharmaceuticals Inc., presented two studies at the American Society of Hematology Annual Meeting in San Diego, which showed patients who were newly diag...

Heart trial success will give Xarelto edge

Janssen and Bayer have stopped a phase 3 trial of Xarelto early after results showed it can cut deaths, heart attacks and strokes compared to aspirin. The promising data paves the way for a lucrativ...

Janssen: Less Bleeding with Xarelto in Some Patients

NewsPhase 3b study shows significantly less bleeding with Xarelto (rivaroxaban) compared to Warfarin in people with non-valvular atrial fibrillation following percutaneous coronary intervention with s...

Phase III COMPASS study of Xarelto stopping early for ‘overwhelming efficacy’

The Phase III trial COMPASS evaluating the efficacy and safety of Xarelto (rivaroxaban) for the prevention…

FDA clears Xarelto blood thinner despite faulty trial device

The U.S. Food and Drug Administration on Tuesday said it has determined the widely-used blood thinner Xarelto to be safe and effective for patients with the heart condition atrial fibrillation after s...

U.S. FDA clears Xarelto blood thinner despite faulty trial device

Oct 11 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it has determined the widely-used blood thinner Xarelto to be safe and effective for patients with the heart condition atrial f...

Matching PubMed Articles

Caution When Prescribing Xarelto to First-Time Patients.

Praxbind Available as Antidote to Bleeding from Pradaxa.

Drug interaction: dabigatran (Pradaxa) and statins.

Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review.

Direct oral anticoagulants (DOACs) are in wide use among patients requiring both short- and long-term anticoagulation, mainly due to their ease of use and the lack of monitoring requirements. With gro...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement